(AOF) – Guerbet has announced the approval by the European Medicines Agency (EMA) of its brand name Elucirem for Gadopiclenol. Gadopiclenol is an investigational gadolinium-based macrocyclic MRI contrast medium. Guerbet announced on February 24, 2022 the acceptance of the EMA to assess the centralized marketing authorization application for Gadopiclenol.
“We are delighted with the approval of the Elucirem brand name for Gadopiclenol in Europe. This step aligns with our preparation for its future commercialization in Europe, if approved,” said David Hale, Managing Director of the Guerbet Group.
AOF – LEARN MORE
Oncology supports laboratory performance
Oncology generated $163 billion in revenue in 2021 (out of an industry total of $613 billion), up 11.9%, according to GlobalData. Its average annual growth has reached 15.4% over the past twenty years. This segment, which is increasingly competitive, is dominated by a few heavyweights such as MSD (Merck & Co. Inc), Roche, BMS
.
L
‘
immuno-oncology, the specialty that has been driving this market for ten years, supports research. GlobalData estimates that this segment could reach 180 billion in 2026. The major players are looking to strengthen themselves in this niche. Pfizer recently acquired Canadian biotech Trillium Therapeutics for $2.3 billion. Following this operation, the American group got hold of two promising molecules in the treatment of blood cancer.